CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 521 enrolled
Drug / intervention
Oral semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04109547
NCT04109547Phase 3Completed

China Multi-regional Clinical Trial: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Novo Nordisk A/S·interventional·Posted Sep 30, 2019·Updated Sep 19, 2024

In Brief

A Phase 3 clinical trial evaluating Oral semaglutide and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 521 participants across 66 sites in 6 countries.

Detailed Summary

The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo. The study will also test if semaglutide is safe. Participants will either get semaglutide or placebo - which treatment is decided by chance. Participants will get 1 tablet a day to take with up to half a glass of water. Participants must take the tablet first thing in the morning on an empty stomach. After taking the tablet, participants must not eat or drink anything for at least 30 minutes. After the 30 minutes, participants can have their first meal of the day and take any other medicines they may need. The study will last for about 8 months (36 weeks). Participants will have 9 clinic visits and 2 phone calls with the study doctor. At all 9 of the clinic visits, participants will have blood samples taken. At 5 of the clinic visits, participants must arrive fasting. This means they cannot eat for 8 hours before the visit. It is fine to drink water up to 2 hours before the visit. This is for some of the blood samples that will be taken at the visit. Women cannot take part if pregnant, breastfeeding or planning to become pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAlgeria, China, Hungary, Serbia, Taiwan, Ukraine
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedSep 30, 2019
Enrollment StartOct 1, 2019
Primary CompletionSep 23, 2021
Study CompletionOct 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.8 years ago

Interventions

Oral semaglutidedrug

Tablets to be taken once-daily for 26 weeks

Placebodrug

Tablets to be taken once-daily for 26 weeks